GOSS
Price
$1.84
Change
+$0.06 (+3.37%)
Updated
Jul 25 closing price
Capitalization
418.24M
17 days until earnings call
ONC
Price
$291.47
Change
-$4.99 (-1.68%)
Updated
Jul 25 closing price
Capitalization
32.77B
11 days until earnings call
Interact to see
Advertisement

GOSS vs ONC

Header iconGOSS vs ONC Comparison
Open Charts GOSS vs ONCBanner chart's image
Gossamer Bio
Price$1.84
Change+$0.06 (+3.37%)
Volume$2.09M
Capitalization418.24M
BeOne Medicines
Price$291.47
Change-$4.99 (-1.68%)
Volume$171.23K
Capitalization32.77B
GOSS vs ONC Comparison Chart in %
Loading...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ONC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GOSS vs. ONC commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GOSS is a Hold and ONC is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (GOSS: $1.84 vs. ONC: $291.47)
Brand notoriety: GOSS and ONC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GOSS: 87% vs. ONC: 50%
Market capitalization -- GOSS: $418.24M vs. ONC: $32.77B
GOSS [@Biotechnology] is valued at $418.24M. ONC’s [@Biotechnology] market capitalization is $32.77B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GOSS’s FA Score shows that 0 FA rating(s) are green whileONC’s FA Score has 0 green FA rating(s).

  • GOSS’s FA Score: 0 green, 5 red.
  • ONC’s FA Score: 0 green, 5 red.
According to our system of comparison, both GOSS and ONC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GOSS’s TA Score shows that 4 TA indicator(s) are bullish while ONC’s TA Score has 5 bullish TA indicator(s).

  • GOSS’s TA Score: 4 bullish, 4 bearish.
  • ONC’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both GOSS and ONC are a good buy in the short-term.

Price Growth

GOSS (@Biotechnology) experienced а +8.24% price change this week, while ONC (@Biotechnology) price change was -1.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.58%. For the same industry, the average monthly price growth was +17.35%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

GOSS is expected to report earnings on Nov 06, 2025.

ONC is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+7.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ONC($32.8B) has a higher market cap than GOSS($418M). GOSS YTD gains are higher at: 103.405 vs. ONC (57.799). GOSS has higher annual earnings (EBITDA): -35.7M vs. ONC (-116.48M). ONC has more cash in the bank: 2.52B vs. GOSS (258M). GOSS has less debt than ONC: GOSS (203M) vs ONC (997M). ONC has higher revenues than GOSS: ONC (4.18B) vs GOSS (125M).
GOSSONCGOSS / ONC
Capitalization418M32.8B1%
EBITDA-35.7M-116.48M31%
Gain YTD103.40557.799179%
P/E RatioN/AN/A-
Revenue125M4.18B3%
Total Cash258M2.52B10%
Total Debt203M997M20%
FUNDAMENTALS RATINGS
GOSS vs ONC: Fundamental Ratings
GOSS
ONC
OUTLOOK RATING
1..100
820
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
60
Fair valued
PROFIT vs RISK RATING
1..100
10071
SMR RATING
1..100
10093
PRICE GROWTH RATING
1..100
3640
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5046

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GOSS's Valuation (57) in the Pharmaceuticals Major industry is in the same range as ONC (60) in the Biotechnology industry. This means that GOSS’s stock grew similarly to ONC’s over the last 12 months.

ONC's Profit vs Risk Rating (71) in the Biotechnology industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that ONC’s stock grew similarly to GOSS’s over the last 12 months.

ONC's SMR Rating (93) in the Biotechnology industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that ONC’s stock grew similarly to GOSS’s over the last 12 months.

GOSS's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as ONC (40) in the Biotechnology industry. This means that GOSS’s stock grew similarly to ONC’s over the last 12 months.

GOSS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as ONC (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to ONC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GOSSONC
RSI
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
80%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
69%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
75%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
73%
Advances
ODDS (%)
Bullish Trend 10 days ago
83%
Bullish Trend 9 days ago
76%
Declines
ODDS (%)
Bearish Trend 27 days ago
88%
Bearish Trend 16 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
75%
Aroon
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ONC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SLVDF0.230.02
+11.86%
Silver Dollar Resources Inc.
HLFFF10.690.19
+1.86%
Hellofresh SE
AMFPF23.85N/A
N/A
Amplifon S.p.A.
NRSAF0.94N/A
N/A
Norse Atlantic ASA
PROSY12.13-0.01
-0.08%
Prosus NV

GOSS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with MEIP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then MEIP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GOSS
1D Price
Change %
GOSS100%
+3.37%
MEIP - GOSS
46%
Loosely correlated
+2.12%
ABEO - GOSS
43%
Loosely correlated
-1.80%
APVO - GOSS
41%
Loosely correlated
-4.67%
SLDB - GOSS
37%
Loosely correlated
+4.79%
AUPH - GOSS
37%
Loosely correlated
-1.54%
More

ONC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ONC has been loosely correlated with ZLAB. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ONC jumps, then ZLAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ONC
1D Price
Change %
ONC100%
-1.68%
ZLAB - ONC
54%
Loosely correlated
-1.59%
MDGL - ONC
42%
Loosely correlated
-0.26%
WXXWY - ONC
37%
Loosely correlated
+4.87%
AXON - ONC
37%
Loosely correlated
+3.63%
GOSS - ONC
35%
Loosely correlated
+3.37%
More